← All trials
NCT06195982
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 6, 2024
- Primary completion
- Feb 28, 2027
- Completion date
- Feb 28, 2027
- First posted
- Jan 8, 2024
- Last posted
- Jul 11, 2024
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- American Heart AssociationCollaborator
- Duke UniversityOfficial
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.